Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

Woo, Marcel S; Steins, David; Häußler, Vivien; Kohsar, Matin; Haag, Friedrich; Elias-Hamp, Birte; Heesen, Christoph; Lütgehetmann, Marc; Wiesch, Julian Schulze zur; Friese, Manuel A.

doi:10.1007/s00415-020-10046-8

Cited by 26 publications

(30 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, both of our patients who have been treated with rituximab-based chemoimmunotherapy failed to seroconvert to SARS-CoV‑2. Similar results were reported in patients with autoimmune disease who have undergone treatment with the anti-CD20 monoclonal antibodies rituximab and ocrelizumab [ 20 – 22 ]. Therefore, serology testing for SARS-CoV‑2 might not be a reliable tool to detect COVID-19 infection in cancer patients treated with anti-CD20 therapy.…”

Section: Discussionsupporting

confidence: 84%

Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers

Fong¹,

Nicolò²,

Alber³

et al. 2021

Wien Klin Wochenschr

View full text Add to dashboard Cite

Background It has been assumed that cancer patients, especially those undergoing chemotherapy, are at increased risk for infection and severe illness from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the general population. After the first alert message from the local healthcare service, a series of drastic measures were taken at our outpatient clinic to contain the spread of coronavirus disease 2019 (COVID-19). Methods In this retrospective study, all consecutive cancer outpatients completed a baseline SARS-CoV-2 test via real-time polymerase chain reaction (RT-PCR) from 15 March to 26 May 2020. In the later phase, after the peak of the pandemic, patients as well as healthcare workers were tested for anti-SARS-CoV-2 IgG antibodies. Results Between 15 March and 26 May 2020, 0.78% (N = 5/640) cancer patients tested positive for SARS-CoV-2 by RT-PCR. Between 22 June and 17 July 2020, anti-SARS-CoV-2 IgG antibodies were detected in 2 out of 250 (0.8%) cancer patients and 2 out of 36 (5.5%) healthcare workers. In only 1 out of 4 cancer patients with confirmed COVID-19 infection, could SARS-CoV-2 antibodies be detected. Conclusion Our findings suggest that the majority of our patients and healthcare workers had not been infected with SARS-CoV-2 and rapidly implemented measures were effective. Maintenance of preventive Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

show abstract

Section: Discussionsupporting

confidence: 84%

Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers

Fong¹,

Nicolò²,

Alber³

et al. 2021

Wien Klin Wochenschr

View full text Add to dashboard Cite

show abstract

“…( Loonstra et al, 2020 ) 3-50 -year-old Female, SPMS,EDSS:6, no comorbidity . ( Sormani et al, 2020 ) 104 306 3(0.9%) Rituximab ( Safavi et al, 2020 , Louapre et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Montero-Escribano et al, 2020 , Meca-Lallana et al, 2020 , Devogelaere et al, 2020 , Woo et al, 2020 , Wurm et al, 2020 , Sahraian et al, 2020 , Maillart et al, 2020 ) 88 1-42 -year-old Male, RRMS, Comorbidities: history of Hodgkin lymphoma and venous thrombosis ( Parrotta et al, 2020 ) 2- 46 -year-old Female, SPMS, EDSS:6.5 and history of hypothyroidism ( Barzegar et al, 2020 ) 3-54 -year-old Female, SPMS, EDSS:7(65) Two other patients ( Sahraian et al, 2020 ) 25 113 5(4%) Anti-CD20 monoclonal antibodies ( Dalla Costa et al, 2020 , Nesbitt et al, 2020 ) 49 49 0 Mycophenolate Mofetil ( Louapre et al, 2020 ) 3 3 0 Cyclophosphamide ( Louapre et al, 2020 ) 1 1 0 Methotrexate ( Louapre et al, 2020 , Sormani et al, 2020 ) 1 1 2 0 Azathioprine ( Sahraian et al, 2020 , Crescenzo et al, 2020 , Sormani et al, 2020 ) ...…”

Section: Resultsmentioning

confidence: 99%

“…Similarly, negative serologic responses were seen in COVID infected patients treated with Rituximab as well. ( Woo et al, 2020 , Wurm et al, 2020 )…”

Section: Resultsmentioning

confidence: 99%

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Dorche

Sahraian

Fadda

et al. 2021

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…The best search term with 279 hits turned out to be coronavirus_multiple sclerosis. Finally, all case reports as well as all case series and larger studies which contained information on the different DMTs and the outcome of the respective patients were included [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ].…”

Section: Methodsmentioning

confidence: 99%

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

Möhn

Konen

Pul

et al. 2020

JCM

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a challenge for all participants in the healthcare system. At the beginning of the pandemic, many physicians asked themselves what risk their patients, especially those with chronic diseases, were exposed to. We present an overview of all patients with multiple sclerosis (MS) and SARS-CoV-2 infection published in the literature so far. In total, there are publications on 873 SARS-CoV-2 positive MS patients and information on the outcome can be given for 700 patients. With regard to the different disease modifying therapies (DMTs), by far the most cases were described under anti-CD20 treatment (n = 317). The mortality rate of all MS patients was 4% and a further 3% required invasive or non-invasive ventilation. When looking at the severe and fatal cases, it is particularly noticeable that patients without DMTs, with previous cardiovascular diseases, or with a severe degree of disability are at risk. Immunosuppressive therapy itself does not appear to be a substantial risk factor. Rather, it is reasonable to assume that the therapies could be protective, either directly, by mitigating the cytokine storm, or indirectly, by reducing the disease activity of MS.

show abstract

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

Cited by 26 publications

References 7 publications

Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers

Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

Contact Info

Product

Resources

About